Peter W. Rodino III, Esq., J.D. Net Worth

The estimated Net Worth of Peter W Iii Rodino is at least $748 Thousand dollars as of 6 May 2024. Mr Rodino owns over 30,865 units of AIM ImmunoTech Inc stock worth over $65,879 and over the last 11 years he sold AIM stock worth over $0. In addition, he makes $681,862 as COO, Exec. Director of Gov.al Relations, and Gen. Counsel & Sec. at AIM ImmunoTech Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr D AIM stock SEC Form 4 insiders trading

Mr has made over 5 trades of the AIM ImmunoTech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 30,865 units of AIM stock worth $12,655 on 6 May 2024.

The largest trade he's ever made was buying 80,646 units of AIM ImmunoTech Inc stock on 3 January 2023 worth over $25,000. On average, Mr trades about 3,479 units every 51 days since 2013. As of 6 May 2024 he still owns at least 212,583 units of AIM ImmunoTech Inc stock.

You can see the complete history of Mr Rodino stock trades at the bottom of the page.

Mr. Peter W. Rodino III, Esq., J.D. biography

Peter W. Rodino III, Esq., J.D. is the COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. at AIM ImmunoTech Inc.

What is the salary of Mr D?

As the COO, Exec. Director of Gov.al Relations, and Gen. Counsel & Sec. of AIM ImmunoTech Inc, the total compensation of Mr D at AIM ImmunoTech Inc is $681,862. There are 4 executives at AIM ImmunoTech Inc getting paid more, with William Mitchell having the highest compensation of $1,696,680.

How old is Mr D?

Mr D is 70, he's been the COO, Exec. Director of Gov.al Relations, and Gen. Counsel & Sec. of AIM ImmunoTech Inc since . There are 3 older and 9 younger executives at AIM ImmunoTech Inc. The oldest executive at AIM ImmunoTech Inc is William Mitchell, 81, who is the Chairman of the Board.

What's Mr D's mailing address?

Peter's mailing address filed with the SEC is 2117 SOUTHWEST HIGHWAY 484, , OCALA,, FL, 34473.

Insiders trading at AIM ImmunoTech Inc

Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors, and Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.

What does AIM ImmunoTech Inc do?

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as

Complete history of Mr Rodino stock trades at AIM ImmunoTech Inc

AIM ImmunoTech Inc executives and stock owners

AIM ImmunoTech Inc executives and other stock owners filed with the SEC include:

• William Mitchell,
  Chairman of the Board
• Thomas K. Equels Esq., J.D., M.S.,
  Exec. Vice Chairman, CEO & Pres
• Thomas Equels,
  Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
• Thomas K. Equels,
  Exec. Vice Chairman, CEO & Pres
• Peter W. Rodino III, Esq., J.D.,
  COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.
• Wayne Springate,
  Senior Vice President - Operations
• David Strayer,
  Chief Scientific & Medical Officer
• Ellen M. Lintal,
  CFO & Chief Accounting Officer
• Charles Jones,
  Investor Relations
• Stewart Appelrouth,
  Director
• Peter Rodino,
  Chief Operating Officer, General Counsel, Secretary
• Ellen Lintal,
  Chief Financial Officer
• Jodie Pelz,
  Controller
• Dr. David R. Strayer M.D.,
  Chief Scientific Officer & Medical Director
• Robert Dickey IV, M.B.A.,
  Chief Financial Officer
• Dr. Ralph Christopher Cavalli Ph.D.,
  VP of QC & Manufacturing
• Dr. Ralph Christopher Cavalli,
  VP of QC & Manufacturing
• Julie Mierau,
  Controller
• Dr. Carol A. Smith,
  Chief Manufacturing Officer & Deputy Chief Scientific Officer
• Ann Marie E. Coverly,
  Director of Admin. & HR and Deputy Investor Relations Coordinator
• Dr. David R. Strayer,
  Chief Scientific Officer & Medical Director
• Roy Robinson,
  Director
• Douglas Hillman,
  President, CEO and Director
• Donald Russell,
  Director
• Thomas E Whytas,
  Director
• David M Vosen,
  Director
• Technik Industries, Inc. El...,
  10% owner
• Kevin J Purcell,
  EVP and Chief Financial Office
• Robert J Mcgill,
  Director
• Mark Perkins,
  Executive V.P.
• Thomas Wright Cason,
  Executive Vice President, COO
• Commercial Bank First,
  10% owner
• Carmelo Russo,
  Executive V.P.
• David A Baldini,
  President and CEO
• Gary E Colbert,
  Executive VP and CFO
• J Mervyn Nabors,
  10% owner
• Nancy Bryan,
  Director